A meta-analysis of phase III data in patients with multiple myeloma who were eligible for autologous stem-cell transplantation has shown that bortezomib induction is the superior induction treatment option available. Patient-level data from three major studies (IFM 2005-01, HOVON-65/GMMG-HD4 and PETHEMA) and >1,500 patients were included in the analysis, which compared bortezomib–dexamethasone, vincristine–doxorubicin–dexamethasone, bortezomib–doxorubicin–dexamethasone, bortezomib–thalidomide–dexamethasone and thalidomide–dexamethasone regimens. Bortezomib-based induction extended progression-free survival and overall survival compared with non-bortezomib-based regimens, and was well tolerated. Importantly, these regimens improved responses of patients who received the stem-cell transplantations compared with the alternatives.
References
Sonneveld, P. et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J. Clin. Oncol. 10.1200/JCO.2012.48.4626
Rights and permissions
About this article
Cite this article
Induction with bortezomib improves response in myeloma. Nat Rev Clin Oncol 10, 547 (2013). https://doi.org/10.1038/nrclinonc.2013.149
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.149